CommentaryBrodalumab and suicidal ideation in the context of a recent economic crisis in the United States
References (9)
- et al.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial
Lancet
(2006) - et al.
Increase in state suicide rates in the USA during economic recession
Lancet
(2012) - et al.
Association of patient-reported psoriasis severity with income and employment
J Am Acad Dermatol
(2007) - Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque...
Cited by (38)
Suicidal ideation during COVID-19: The contribution of unique and cumulative stressors
2022, Psychiatry ResearchCitation Excerpt :Suicidal ideation (SI), or the act of contemplating suicidal behaviors, has been shown to increase during acute personal crises (Danesh and Kimball, 2016; Economou et al., 2013; Harmer et al., 2021).
Psoriasis in Taiwan: From epidemiology to new treatments
2018, Dermatologica SinicaCitation Excerpt :Exacerbation of ulcerative colitis and Crohn's disease in in vitro and in vivo studies reminded prescribers to be cautious when using them in patients with inflammatory bowel diseases.112,113 Suicidal ideation and adverse behavioral events have been reported with brodalumab, an anti-IL-17-receptor antibody and are of significant concern.114–117 Paradoxical exacerbation of psoriasis was caused not only by anti-TNF-α drugs but was also reported in a case report after the switch from infliximab to secukinumab.118
Dermatologic Conditions and Risk of Suicide: A Case-Control Study
2018, PsychosomaticsCitation Excerpt :Patients diagnosed with conditions such as acne, psoriasis, and atopic dermatitis have been identified to have an increased risk of depression and suicidal ideations.12–16 Although there is paucity of data on risk of suicide death with dermatologic conditions, this concern has affected both clinical practice and research.17,18 The ongoing treatment utilization before suicide study, funded by the National Institute of Mental Health, is investigating the association between nonpsychiatric clinical factors such as medical conditions and suicide risk.11
IL-17 for therapy
2017, Journal of Dermatological ScienceCitation Excerpt :An unforeseen slight raise in suicide attempts and suicidal ideation was observed in the initial trials performed by Amgen with Brodalumab. Whether this increased suicidal risk is indeed caused by Brodalumab treatment is still under debate [68,69]. For some inflammatory diseases IL-17 neutralization may be contraindicated: Although IL-17 is thought to be implicated in Crohn’s disease, a proof of concept trial in CD using Secukinumab had to be discontinued due to adverse side effects [70].
Psoriasis and Psychiatric Disorders: The Next Frontier
2017, Actas Dermo-Sifiliograficas
Funding sources: None.
Disclosure: Dr Kimball has been a consultant and investigator for Amgen, Abbvie, Janssen, Novartis, Celgene, and Pfizer; has been a consultant for Eli Lilly; and has fellowship funding from Janssen. Ms Danesh has no conflicts of interest to declare.